Palisade Bio
PALI
1 hedge funds and large institutions have $11.7M invested in Palisade Bio in 2013 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0.04% less ownership
Funds ownership: 5.29% → 5.25% (-0.04%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $1.15M
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAFNA Capital Management
Los Angeles,
California
|
-$847K |
| 2 |
First Allied Advisory Services
San Diego,
California
|
-$231K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$29K |
| 4 |
D.E. Shaw & Co
New York
|
-$28K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$9K |
PALI Hedge Fund Activity: Q4 2013 in Review
1 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q4 2013, worth a combined $11.7M — up 7.6% from $10.8M a quarter earlier.
Fund positioning in PALI was balanced in Q4 2013: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was DAFNA Capital Management, cutting an estimated $847K.
- 1 institutional investor held Palisade Bio (PALI) as of Q4 2013, unchanged from Q3 2013.
- Funds reported $11.7M of Palisade Bio stock for Q4 2013, up 7.6% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q4 2013 and 0 closed out.
- The largest Palisade Bio seller in Q4 2013 was DAFNA Capital Management, an estimated $847K sold.
Based on aggregated 13F filings for Q4 2013.